1rev image
Deposition Date 1995-09-17
Release Date 1996-10-14
Last Version Date 2024-10-23
Entry Detail
PDB ID:
1REV
Title:
HIV-1 REVERSE TRANSCRIPTASE
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.60 Å
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:HIV-1 REVERSE TRANSCRIPTASE
Gene (Uniprot):gag-pol
Chain IDs:A
Chain Length:560
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:HIV-1 REVERSE TRANSCRIPTASE
Gene (Uniprot):gag-pol
Chain IDs:B
Chain Length:440
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
CSD A CYS 3-SULFINOALANINE
Primary Citation

Abstact

BACKGROUND HIV reverse transcriptase (RT) is a key target of anti-AIDS therapies. Structural studies of HIV-1 RT, unliganded and complexed with different non-nucleoside inhibitors (NNIs), have pointed to a common mode of binding and inactivation through distortion of the polymerase catalytic site by NNIs containing two hinged rings. The mode of binding of the TIBO family of inhibitors is of interest because these compounds do not fit the two-hinged-ring model. RESULTS The structure of HIV-1 RT complexed with 9-chloro-TIBO (R82913) has been determined at 2.6 A resolution. As reported for the lower resolution analysis of another TIBO compound, this inhibitor binds at the same site as other NNIs, but our higher resolution study reveals the Cl-TIBO is distorted from the conformation seen in crystals of the inhibitor alone. This allows Cl-TIBO to mimic the binding of NNIs containing two hinged rings. Inhibitor-protein interactions are again predominantly hydrophobic and the protein conformation corresponds to that seen in complexes with other tight-binding NNIs. CONCLUSIONS Although Cl-TIBO is chemically very different from other NNIs, it achieves remarkable spatial equivalence and shape complementarity with other NNIs on binding to RT. Comparison of the different RT-NNI complexes suggests modifications to the TIBO group of inhibitors which might enhance their binding and hence, potentially, their therapeutic efficacy.

Legend

Protein

Chemical

Disease

Primary Citation of related structures